MENU

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone

Sestak, I; Martin, M; Dubsky, P; Kronenwett, R; Rojo, F; Cuzick, J; Filipits, M; Ruiz, A; Gradishar, W; Soliman, H; Schwartzberg, L; Buus, R; Hlauschek, D; Rodriguez-Lescure, A; Gnant, M

BREAST CANCER RESEARCH AND TREATMENT
2019
VL / 176 - BP / 377 - EP / 386
abstract
PurposeEndoPredict (EPclin) is a prognostic test validated to inform decisions on adjuvant chemotherapy to endocrine therapy alone for patients with oestrogen receptor-positive, HER2-negative breast cancer. Here, we determine the performance of EPclin for estimating 10-year distant recurrence-free interval (DRFI) rates for those who received adjuvant endocrine therapy (ET) alone compared to those with chemotherapy plus endocrine therapy (ET+C).MethodsA total of 3746 women were included in this joint analysis. 2630 patients received 5years of ET alone (ABCSG-6/8, TransATAC) and 1116 patients received ET+C (GEICAM 2003-02/9906). The primary objective was to evaluate the ability of EPclin to provide an estimate of the 10-year DR rate as a continuous function of EPclin separately for ET alone and ET+C. Cox proportional hazard models were used for these analyses.ResultsEPclin was highly prognostic for DR in women who received ET alone (HR 2.79 (2.49-3.13), P<0.0001) as well as in those who received ET+C (HR 2.27 (1.99-2.59), P<0.0001). Women who received ET+C had significantly smaller increases in 10-year DR rates with the increasing EPclin score than those receiving ET alone (EPclin=5; 12% ET+C vs. 20% ET alone). We observed a significant positive interaction between EPclin and treatment groups (P-(interaction)=0.022).ConclusionsIn this comparative non-randomised analysis, the rate of increase in DR with EPclin score was significantly reduced in women who received ET+C versus ET alone. Our indirect comparisons suggest that a high EPclin score can predict chemotherapy benefit in women with ER-positive, HER2-negative disease.
187th Global

AccesS level

Green Published, Other Gold

Mentions data

PAPER MENTIONS
Clinical Medicine
  •   Twitter
  • 1
  •   Wikipedia
  • 0
  •   News
  • 110
  •   Policy
  • 0
Global Ranking
  •   Twitter
  • 1
  •   Wikipedia
  • 0
  •   News
  • 110
  •   Policy
  • 0

Mentions Chart

Influratio by dimension
  • Twitter
  • Wikipedia
  • News
  • Policy
PAPER MENTIONS
  •   Twitter
  • 1
  •   Wikipedia
  • 0
  •   News
  • 110
  •   Policy
  • 0
PROYECTO FINANCIADO POR PLAN NACIONAL DE INVESTIGACIÓN AGENCIA ESTATAL DE INVESTIGACIÓN, MINISTERIO DE CIENCIA E INNOVACIÓN. PID2019-109127RB-I00